メインのコンテンツにスキップする

申し訳ございませんが、お客様のブラウザには完全に対応しておりませんオプションがありましたら、新しいバージョンにアップグレードするか、 Mozilla Firefox、 Microsoft Edge、Google Chrome、またはSafari 14以降をお使いください。これらが利用できない場合、またサポートが必要な場合は、フィードバックをお送りください。

この新ホームページへのフィードバックを歓迎します。ご意見をお寄せください 新しいタブ/ウィンドウで開く

Elsevier
論文を投稿する

Dr. V. Craig Jordan

DVCJ

Dr. V. Craig Jordan

Author profile 新しいタブ/ウィンドウで開く

Professor of Breast Medical Oncology, Professor of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX. Previously, he was Chief Scientific Officer and Vice President of Oncology at Georgetown University's Lombardi Comprehensive Cancer Center. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant antihormone therapy. More recently, his work has branched out into the prevention of multiple diseases in women with the discovery of the selective estrogen receptor modulator (SERM) group of drugs. Currently, she plans to develop a new Hormone Replacement Therapy (HRT) for postmenopausal women that prevents breast cancer and does not increase the risk of breast cancer. Affiliations and Experience Professor of Breast Medical Oncology, Professor of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.